Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
  • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
  • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
  • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
  • A61K47/38—Cellulose; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
  • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/08—Antiepileptics; Anticonvulsants

Definitions

• the present invention provides film or wafer compositions of midazolam for use in the treatment of seizures eg in connection with epilepsy or febrile seizures.
• the film- compositions are intended for administration to the oral cavity in the form of a bio- adhesive film or wafer.
• the composition makes it possible to administer the drug substance, midazolam, to a patient, even if the patient is unconscious and it avoids the risk that the patient receives a too low dose eg if a solution is administered, and some of the applied solution may flow out of the mouth instead of being absorbed by the oral mucosa.
• Midazolam is a well-documented drug substance with sedative, anxiolytic, amnesic and hypnotic properties.
• Midazolam acts on nerve cells in the brain and is used to control convulsions (fits or seizures) in children and adults with epilepsy or other diseases associated with sei- Kires, or in children with febrile seizures.
• the brain and nerves are made up of many nerve cells that communicate with each other through electrical signals. These signals must be carefully regulated for the brain and nerves to function properly.
• Midazolam works by amplifying the action of the neurotransmitter GABA in the brain. GABA is involved in transmitting messages between the nerve cells and acts as a natural 'nerve-calming' agent. It helps keep the nerve activity in the brain in balance, and is involved in inducing sleepiness, reducing anxiety and relaxing muscles.
• Midazolam is commercially available in the form of its hydrochloride, for example in the form of a glycerine-based syrup sold under the trade name VERSED®, which contains 2.5 mg/mL of midazolam.
• Midazolam is also marketed in the form of its maleate salt for example in tablets containing 7.5 or 15 mg per tablet under the trademark DOR- MICUM®.
• Products, which are formulated for administration via the buccal route, are EPISTATUS® (10 mg/mL midazolam in liquid form) and BUCCOLAM® (2.5mg/0.5 mL, 5 mg/mL, 7.5 mg/mL or 10 mg/2 mL midazolam in liquid form).
• EP-B-1 323 422 (Special Products Limited) relates to a liquid midazolam composition, which contains a higher concentration of midazolam than prior art compositions.
• the composition contains midazolam maleate dissolved in an aqueous liquid medium containing ethanol and a polyhydroxy solvent such as glycerol or propylene glycol.
• buccally administered midazolam given in recommended doses shows a rapid absorp- tion. Furthermore, the achieved plasma levels are sufficient to provide therapeutic effect in the patient.
• the present invention addresses the above-mentioned needs and provides a composition in the form of a film or wafer containing midazolam for application to the oral mu- cosa or tongue.
• the film in unit dose form typically contains from 0.25 to 2 mg midazolam either in the form of midazolam or a pharmaceutically acceptable salt thereof.
• buccal administration of a dose of 1 mg midazolam in the form of a film preparation according to the invention to an adult with a weight of 90 kg leads to a plasma level that is therapeutically effective (about 5 ng/mL).
• An important object of the invention is to provide a film preparation that is suitable for use in children suffering from seizures and the examples herein indicate that a film preparation according to the invention containing 1 mg or less such as 0.75 mg, 0.5 mg or 0.25 mg or even as low as 0.1 mg of midazolam will be suitable for administration to children to achieve the desired and fast therapeutic effect.
• the dose will depend on the weight of the child.
• a low-dose midazolam composition, which at the same time is therapeutically effective, is expected to have substantial impact on the safe use of the drug.
• Known side-effects are respiratory depression, respiratory arrest, apnoea, hypotension, bradycardia, heart arrest, death.
• the present inventor has found that buccal administration of midazolam via a film or wafer composition is very efficient and a dose as low as 2 mg leads to blood levels of 5-10 ng/mL in adult volunteers. Even a dose of 1 mg to adults with an average body weight of 90 kg results in therapeutic levels of midazolam. There is a linear relationship between dose and plasma level and therefore the dose to children could be as low as 0.01 1 mg/kg body weight (corresponding to 0.22 mg for a child weighing 20 kg)
• midazolam should be from about 5 to about 20 ng/mL to obtain the desired effect in the management of seizures.
• seizures include febrile seizures, acute seizure and status epilepticus.
• Epileptic seizures convulsive status epilepticus
• seizures are a common cause of neurological medical emergency and often result in brain damage. Failure to relieve the symptoms of an epileptic fit in less than about 15 minutes can lead to death. Thus, it is extremely important to treat the patient promptly and to relieve the symptoms as quickly as possible in order to minimize the risk of brain damage of death of the patient.
• midazolam may be used in the form of midazolam or in the form of pharmaceutically acceptable salts thereof.
• Such salts include salts formed from inorganic or organic acids such as hydrochloride, sulfate, phosphate, ma- leate, fumarate and the like. In the event a salt is employed, the amount of midazolam in the film is given as the free base.
• a film or wafer composition according to the invention typically contains a film-forming substance.
• Film-forming agents suitable for use include cellulose and cellulose derivatives such as ethylcellulose, methylcellulose, hydroxypro- pyl methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, carboxymethyl- cellulose (and its sodium salt), microcrystalline cellulose, crosscarmellose, cellulose acetate; polysaccharides such as alginate (or alginic acid), pectin, tragacanth, carrageenan, dextrans, gelatin, sclerogucan, xanthan gum, guar gum:
• HPMC hydroxypropyl methylcellulose
• Suitable grades of HPMC and possible other film-forming agents for use in an oral film according to the invention are described herein.
• the concentration of HPMC(s) in a film is normally in a range of from 35 to 99% w/w.
• the total concentration of HPMCs may be from about 40 to about 99% w/w, from about 45 to about 99% w/w or from about 50 to 99% w/w.
• the range may be from 80 to 99% w/w, notably about 98% w/w.
• the % w/w are given based on total dry matter in the film.
• the HPMC for use in a film according to the invention may be as specified in Ph. Eur., it may be type 2910 and/or it may be a mixture of two or more HPMCs having different viscosities.
• the concentrations in the film of the two or more HPMCs having different viscosity may be the same or different, notably the same.
• the concentration of the first HPMC may be from 25-50 % w/w and the concentration of the second HPMC may be from 10-45% w/w and the sum concentration of the two HPMCs is from 35-99% w/w.
• the individual concentration may span over the range 10-50% w/w of each HPMC and the sum concentration of all HPMCs is from 35-99% w/w.
• HPMCs may have a viscosity of 3 mPa s and 50 mPa s, respectively.
• a film according to the present invention may contain a mixture of HPMCs having a viscosity of 3 mPa s and 50 mPa s, respectively.
• the total concentration of HPMCs may be as described above.
• the individual concentrations of HPMC 3 mPa s and HPMC 50 mPa s are the same such as, eg, in a range of from 20% w/w to 50% w/w for each HPMC and based on total dry matter in the oral film.
• films with suitable properties are obtained for a film according to the invention that contains a mixture of HPMCs having a viscosity of 3 mPa s and 50 mPa s, respectively, and a total concen- tration of HPMC s of from 80 to 99% w/w (based on total dry matter).
• polyethylene oxide can be obtained with average molecular weights from about 20,000 to about 4,000,000 Daltons
• acrylic polymers can be purchased e.g. with different solubilities in different media.
• the content of film-forming polymer may be varied to adjust the release rate.
• Most of the above-mentioned film-forming substances are also bio-adhesive to a varying degree.
• a composition of the invention may also contain one or more pharmaceutically acceptable excipients or additives including solubilizers, pH adjusting agents, stabilizers, taste-masking agent(s), colouring agents, anti-oxidants (if needed), etc.
• a film or wafer is typically a paper-thin polymer film that is used as carriers for drug substance(s). Normally, a film composition is thicker than a piece of paper, but normally the thickness is 50 - 500 micrometer. A wafer as well as a film is administered orally and does not require water or swallowing.
• the film or wafer typically contain 0.5-20 mg midazolam/g of the film or wafer composition.
• the composition is typically in the form of a unit dose composition and generally, the composition has a weight of from about 50 to about 200 mg.
• the dose is from about 0.01 to 0.2 mg/body weight, but as seen from the examples herein, the dose may be reduced to from about 0.01 -0.1 mg/kg body weight, notably from about 0.01 to 0.02 mg/kg body weight or that each unit dose will contain approximately a dose of 0.1 - 2 mg or from 0.1 to 1 .5 mg or from 0.1 to 1 .0 mg for children and adults weighing 10-90 kg.
• a composition of the invention is typically prepared by dissolving midazolam in a suitable solvent such as a water or ethanol or a water-ethanol mixture.
• a suitable solvent such as a water or ethanol or a water-ethanol mixture.
• the film-forming agent is dissolved either in the same medium or in a solvent or solvent mixture, wherein the film-forming substance is soluble. Water may be included, but should normally not exceed about 50% v/v of the solvent in order to ensure a suitable, not too long dry- ing time.
• the solutions containing midazolam and the film-forming substance are mixed, film-casted and dried. If further excipients/additions are desired in the composition these substances are added to one of the solutions.
• the midazolam and the film- forming substance may also be dissolved in one pot. In some cases, midazolam may be employed in micronized form; this is especially the case if midazolam is not dis- solved or only partly dissolved in the solvent.
• the desired plasma level After application, either on the tongue or the oral mucosa, the desired plasma level will be achieved in 3-5 minutes. Due to the low doses and the fact that the composition does not flow out of the mouth, it is also possible to repeat the dosing, if necessary, al- ready after 10-15 minutes without any risk of side-effects as prolonged drowsiness, respiratory depression etc.
• the film preparations may be used in the treatment of seizures in cats or dogs.
• the dose is believed to be of the same order of magnitude.
• the following examples are for illustrative purposes only and are not intended to limit the scope of the invention.
• HPMC and midazolam is dissolved/dispersed in ethanol-water (5:1 ) mixture and cast- ed. The composition is dried at 40 °C.
• Ethanol-water mixtures can be used, wherein the concentration of ethanol in the final mixture is from 50-100% v/v.
• compositions as described in Example 1 are prepared using:
• Example 2 hydroxypropylcellulose instead of HPMC
• Example 6 Cellulose acetate instead of HPMC
• Example 7 Polyvinyl alcohol instead of HPMC
• Example 9 Dextran 400,000 instead of HPMC
• Example 10 Polyethylene oxide 700,000 instead of HPMC
• Example 20 is repeated, but using a 1 :1 mixture of the stated polymer and HPMC.
• Example 20 is repeated, but using a 1 :1 mixture of the stated polymer and HPMC.
• Hypromellose E3 2.5 g
• Hypromellose E50 2.5 g
• Plasma preparations weighing approximately 0,07 g (1 x 2 cm) containing 2 mg midazo- lam hydrochloride were applied on the oro-mucosal membrane in healthy volunteers (body weight 90 kg). Venous blood samples were drawn 6, 12 and 18 minutes after application. Plasma levels ranging from 3 to 10 ng/mL (measured by LC-MS/MS after liquid extraction) were achieved in the volunteers. The achieved plasma levels in adults will correspond to at least 15-50 ng/mL in children weighing 20 kg. No side-effects were observed. Average plasma levels of 5 ng/mL were obtained as described herein.
• Plasma preparations weighing approximately 0,07 g (1 x 2 cm) containing 1 mg midazo- lam hydrochloride were applied on the oro-mucosal membrane in healthy volunteers (body weight 90 kg). Venous blood samples were drawn 6, 12 and 18 minutes after application. Plasma levels ranging from 1 ng/mL (6 min) to 4.6 ng/mL (12 min) (measured by LC-MS/MS after liquid extraction) were achieved in the volunteers. The achieved plasma levels in adults will correspond to at least 15-20 ng/mL in children weighing 20 kg. No side-effects were observed. Average plasma levels were obtained as described herein.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Inorganic Chemistry (AREA)
• Pain & Pain Management (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Nutrition Science (AREA)
• Physiology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=53785375

Family Applications (1)

Country Status (6)

Cited By (3)

Families Citing this family (1)

Citations (2)

Family Cites Families (5)

• 2016
  • 2016-07-15 ES ES16748275T patent/ES2738652T3/es active Active
  • 2016-07-15 EP EP16748275.1A patent/EP3322402B1/en active Active
  • 2016-07-15 WO PCT/EP2016/066860 patent/WO2017009446A1/en not_active Ceased
  • 2016-07-15 US US15/744,569 patent/US20180221384A1/en not_active Abandoned
  • 2016-07-15 JP JP2018521707A patent/JP2018521139A/ja active Pending
  • 2016-07-15 CN CN201680041767.6A patent/CN108024952A/zh active Pending
• 2020
  • 2020-03-06 US US16/812,151 patent/US20200306260A1/en not_active Abandoned

Patent Citations (2)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events